A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants

Lead Sponsor

Bristol-Myers Squibb

Age

18 - 50 years

Sex

ALL

Healthy Volunteers

Yes

•Normal renal function at screening as evidenced by an estimated glomerular filtration rate (GFR) \> 80 mL/min/1.732 m2 calculated with the Chronic Kidney Disease Epidemiology Collaboration formula.
•Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic onadotropin) within 24 hours prior to the start of study treatment.
•Body mass index of 18.0 kg/m2 to 32.0 kg/m2, inclusive, and body weight ≥ 50 kg, at screening.

•Participants who currently smoke, as well as those who have stopped smoking less than 6 months prior to dosing on Day 1.
•Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population.
•Prisoners or participants who are involuntarily incarcerated
•Any significant acute or chronic medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study, including a history of or active liver disease

Related studies

NCT07310901 · Obese But Otherwise Healthy Participants

NCT06342713 · Healthy Participants, Healthy Subjects, and more

NCT07471204 · Osteoarthritis of Knee, Healthy Participants

NCT07401472 · Healthy Participants Study

NCT07412353 · Healthy Participants